Search

Displaying results 6071 - 6080 of 10000 in total
  1. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.

  2. Drug

    Butyrfentanyl

    go.drugbank.com/drugs/DB09173
    ExperimentalIllicit

    [L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl. … [A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.

  3. Drug

    ChulaCov19 mRNA vaccine

    go.drugbank.com/drugs/DB16445
    Experimental

    The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678]. … Pre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies[L30678].

  4. Drug

    RO7296682

    go.drugbank.com/drugs/DB17531
    Investigational

    RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. … RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T<sub>reg</sub>) cells.

  5. Drug

    Luveltamab tazevibulin

    go.drugbank.com/drugs/DB17563
    Investigational

    [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

  6. Drug

    Puromycin

    go.drugbank.com/drugs/DB08437
    Experimental

    Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. … Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.

  7. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379]. … Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.

    International brands: Rezaltas LD
  8. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. … It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.

  9. Drug

    Itolizumab

    go.drugbank.com/drugs/DB16207
    Investigational

    Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

  10. Drug

    Miridesap

    go.drugbank.com/drugs/DB13087
    Investigational

    Miridesap has been used in trials studying the prevention of HIV and treatment of AL amyloidosis.